Core Viewpoint - The company has completed an additional capital injection of HKD 30 million into its indirect wholly-owned subsidiary TGM, following previous injections totaling HKD 83 million, to strengthen TGM's capital and support its business expansion [1] Group 1: Capital Injection Details - The total paid-in capital of TGM has reached HKD 150 million after the latest capital injection [1] - TGM is a licensed corporation under the Securities and Futures Ordinance in Hong Kong, holding Type 1 and Type 7 licenses, allowing it to engage in securities trading and provide automated trading services [1] Group 2: Financial Performance - For the six months ending September 30, 2025, TGM reported impressive performance with revenues of approximately HKD 449 million, marking a nearly 400% increase compared to the same period last year [1] Group 3: Strategic Implications - The capital enhancement will significantly improve TGM's risk resilience and business capacity, providing a solid foundation for expanding its IPO underwriting and margin financing business [2] - Strengthening the capital base will further enhance TGM's market competitiveness and industry position, creating favorable conditions for exploring emerging business areas [2] - The board believes that this capital injection will lay a solid foundation for TGM's future performance growth, aligning with the best interests of the company and its shareholders [2]
捷利交易宝(08017.HK)进一步对全资附属TradeGo Markets Limited增资3000万港元